Healthcare >> CEO Interviews >> March 2, 2026

Interview with the President and CEO: PDS Biotechnology Corporation (NASDAQ:PDSB)

Bedu-Addo, Frank
Dr. Frank Bedu-Addo has served as President, CEO and a director of PDS Biotechnology Corporation since its inception in 2005. Dr. Bedu-Addo is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of both operational and drug development strategies, supervising and managing both large organizations and emerging biotechnology companies. Dr. Bedu-Addo was a founding and senior executive at KBI BioPharma, Inc. As Vice President of Drug Development, he oversaw all business and drug development operations. Before KBI, he successfully started and managed Cardinal Health’s East Coast biotechnology drug development operations. Prior, Dr. Bedu-Addo was an Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions, he contributed to the development of numerous drugs, including antiviral and anticancer products. Dr. Bedu-Addo obtained his M.S. degree in chemical engineering and a Ph.D. in pharmaceutics from the University of Pittsburgh. Profile
Word count: 4,419

TWST: It’s been a few years since we last spoke. Can you give our readers a refresher on the company and its history?

Dr. Bedu-Addo: So, PDS